Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Novartis AG, a leading name in the pharmaceutical preparation manufacturing industry, is headquartered in Switzerland (CH) and operates extensively across Europe, North America, and Asia. Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has since achieved significant milestones, including the development of groundbreaking therapies in oncology, cardiology, and immunology.
The company is renowned for its innovative products, such as Kymriah, a pioneering CAR-T cell therapy, and Entresto, a heart failure treatment that has transformed patient care. Novartis's commitment to research and development positions it as a market leader, consistently ranking among the top pharmaceutical companies globally. With a focus on improving patient outcomes and advancing healthcare, Novartis continues to shape the future of medicine through its unique and effective solutions.
100
DitchCarbon score
+58 vs industry average
Novartis’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Novartis?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2028
202020212022202320242025202620272028
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Novartis's reported carbon emissions
Novartis, a Pharmaceutical Preparation Manufacturing company headquartered in Switzerland, reported total carbon emissions of 4,377,100,000 kg CO2e in 2025. This figure comprises 192,300,000 kg CO2e from Scope 1, 14,900,000 kg CO2e (market-based) from Scope 2, and 4,169,900,000 kg CO2e from Scope 3 emissions. In comparison, their total emissions were approximately 4,522,600,000 kg CO2e in 2024 and 4,868,900,000 kg CO2e in 2023.
Novartis has set ambitious climate commitments, validated by the Science Based Targets initiative (SBTi). They aim to reduce absolute Scope 1 and 2 GHG emissions by 90% by 2030 from a 2022 base year. Additionally, they are committed to reducing absolute Scope 3 GHG emissions by 42% within the same timeframe. For the longer term, Novartis AG has set an overall net-zero target to reach net-zero greenhouse gas emissions across their value chain by 2040. This includes maintaining a minimum of 90% absolute Scope 1 and 2 emissions reductions from 2030 through 2040 from a 2022 base year, and reducing absolute Scope 3 GHG emissions by 90% by 2040 from a 2022 base year.
The company also aims to become carbon neutral in its own operations (Scope 1 and 2) by 2025. In 2023, Novartis reported a 63% reduction in Scope 1 and 2 emissions (from energy) compared to their 2016 baseline. Furthermore, Novartis is committed to being carbon neutral across all operations, including the value chain, by 2030.
Assessing Novartis as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Novartis and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Novartis’s Climate Goals (2030 & 2050)
5 goals2030
90% reduction in Scope 2
Novartis commits to reduce absolute scope 1 and 2 GHG emissions 90% by 2030 from a 2022 base year.
On track90%
2030
42% reduction in scope 3 total
Novartis also commits to reduce absolute scope 3 GHG emissions 42% within the same timeframe.
At risk42%
2040
90% reduction in scope 3 total
Novartis also commits to reduce absolute scope 3 GHG emissions 90% by 2040 from a 2022 base year.
Behind target90%
See all 5 climate goals
Sign up to see all goals
Already have an account? Sign in now
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
12 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
2030 targetSee details
Active
Carbon Disclosure Project
Sign in to view
Active
The Climate Pledge
Signed 2021See details
Active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
2025 targetSee details
Active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Novartis2 days ago
100
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Frequently asked questions
Common questions about Novartis’s sustainability data and climate commitments
In 2025, Novartis reported total carbon emissions of approximately 4.4 billion kg CO2e. This represents a decrease from previous years, with emissions around 4.5 billion kg CO2e in 2024 and roughly 4.9 billion kg CO2e in 2023. This downward trend indicates progress in managing the company's environmental impact. Novartis, a Swiss-based pharmaceutical preparation manufacturer, tracks these emissions across all scopes to inform its sustainability strategy and demonstrate accountability to stakeholders.
Data year: 2025
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more